Filing Details
- Accession Number:
- 0001601830-24-000025
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-25 18:39:10
- Reporting Period:
- 2024-03-21
- Accepted Time:
- 2024-03-25 18:39:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1601830 | Recursion Pharmaceuticals Inc. | RXRX | Biological Products, (No Disgnostic Substances) (2836) | 464099738 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1856414 | Tina Marriott | 41 S. Rio Grande Street Salt Lake City UT 84101 | President And Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Acquisiton | 2024-03-21 | 8,000 | $1.06 | 647,982 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2024-03-21 | 7,390 | $10.70 | 640,592 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2024-03-21 | 610 | $11.34 | 639,982 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2024-03-21 | 8,000 | $0.00 | 8,000 | $1.06 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 488,000 | 2028-07-22 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | Stock Option (Right to Buy) | $8.55 | 2033-02-01 | 0 | 434,122 | Direct | |
| Class A Common Stock | Stock Option (Right to Buy) | $11.40 | 2032-02-04 | 0 | 159,226 | Direct | |
| Class A Common Stock | Stock Option (Right to Buy) | $11.40 | 2022-02-04 | 2032-02-04 | 0 | 4,784 | Direct |
| Class A Common Stock | Stock Option (Right to Buy) | $2.48 | 2030-12-30 | 0 | 150,000 | Direct | |
| Class A Common Stock | Stock Option (Right to Buy) | $10.09 | 2034-02-09 | 0 | 447,917 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2033-02-01 | 0 | 434,122 | Direct |
| 2032-02-04 | 0 | 159,226 | Direct |
| 2032-02-04 | 0 | 4,784 | Direct |
| 2030-12-30 | 0 | 150,000 | Direct |
| 2034-02-09 | 0 | 447,917 | Direct |
Footnotes
- Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023.
- This transaction was executed in multiple trades at prices ranging from $10.28 to $11.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $11.28 to $11.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
- The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
- The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Billionaire Hedge Funds
